Reversibility of liver failure secondary to metastatic breast cancer by vinorelbine and cisplatin chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 52, Issue 5, 2003, Pages 367-370

  Sharma, Ricky A ^a   Decatris, Marios P ^a   Santhanam, Sundar ^a   Roy, Rajarshi ^a   Osman, Ahmed E ^a   Clarke, Christine B ^a   Khanna, Subhash ^a   O'Byrne, Kenneth J ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Jaundice; Palliation; Platinum; Vinca

Indexed keywords

BILIRUBIN; CISPLATIN; NAVELBINE; PLATINUM DERIVATIVE; VINCA ALKALOID;

ADULT; AGED; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; JAUNDICE; LIVER FAILURE; LIVER FUNCTION; LIVER METASTASIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW DISEASES; BREAST NEOPLASMS; CISPLATIN; FEMALE; HUMANS; LIVER FAILURE; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MIDDLE AGED; PILOT PROJECTS; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; VINBLASTINE;

EID: 0242298098     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0679-8     Document Type: Article

References (18)

1. Hoe Al, Royle GT, Taylor I (1991) Breast liver metastases: incidence, diagnosis and outcome. J R Soc Med 84:714-716
2. Leone BA, Romero A, Rabinovich MG, Vallejo CT, Bianco A, Perez JE, Machiavelli M, Rodriguez R, Alvarez LA (1988) Stage IV breast cancer: clinical course and survival of patients with osseous versus extraosseous metastases at initial diagnosis. The GOCS (Grupo Oncologico Cooperative del Sur) experience. Am J Clin Oncol 11:618-622
3. Vaishampayan U, Parchment RE, Jasti BR, Hussain M (1999) Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology 54 [6 Suppl 1]:22-29
4. Ratain MJ, Tempero M, Skosey CS (2001) Outline of oncology therapeutics. WB Saunders, Philadelphia
5. Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR, Livingston RB (1998) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 16:2459-2465
6. Robieux I, Sorio R, Borsatti E, Cannizzaro R, Vitali V, Aita P, Freschi A, Galligioni E, Monfardini S (1996) Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther 59:32-40
7. Vassilomanolakis M, Koumakis G, Barbounis V, Demiri M, Pateras H, Efremidis AP (2000) Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines. Ann Oncol 11:1155-1160
8. Mustacchi G, Muggia M, Milani S, Ceccherini R, Leita ML, Dellach C (2002) A phase II study of cisplatin and vinorelbine in patients with metastatic breast cancer. Ann Oncol 13:1730-1736
9. Gunel N, Akcali Z, Yamac D, Onuk E, Yilmaz E, Bayram O, Tekin E, Coskun U (2000) Cisplatin plus vinorelbine as a salvage regimen in refractory breast cancer. Tumori 86:283-285
10. Shamseddine AI, Taher A, Dabaja B, Dandashi A, Salem Z, El Saghir NS (1999) Combination cisplatin-vinorelbine for relapsed and chemotherapy- pretreated metastatic breast cancer. Am J Clin Oncol 22:298-302
11. Ray-Coquard I, Biron P, Bachelot T, Guastalla JP, Catimel G, Merrouche Y, Droz JP, Chauvin F, Blay JY (1998) Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline-and/or paclitaxel-containing regimens. Cancer 82:134-140
12. Kosmas C, Agelaki S, Giannakakis T, Mavroudis D, Kouroussis C, Kalbakis K, Papadouris S, Souglakos J, Malamos N, Georgoulias V (2002) Phase I study of vinorelbine and carboplatin combination in patients with taxane and anthracycline pretreated advanced breast cancer. Oncology 62:103-109
13. Daniels S (2001) Dosage adjustment for cytotoxics in hepatic impairment. British Oncol Pharmacy Association, London
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
15. Smith TJ, Hillner BE, Neighbors DM, McSorley PA, Le Chevalier T (1995) Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin and vindesine plus cisplatin for non-small-cell lung-cancer. J Clin Oncol 13:2166-2173
16. Twelves CJ, Richards MA, Smith P, Rubens RD (1991) Epirubicin in breast cancer patients with liver metastases and abnormal liver biochemistry: initial weekly treatment followed by rescheduling and intensification. Ann Oncol 2:663-666
17. Zelek L, Cottu P, Tubiana-Hulin M, Vannetzel JM, Chollet P, Misset JL, Chouaki N, Marty M, Gamelin E, Culine S, Dieras V, Mackenzie S, Spielmann M (2002) Phase II study of oxaliplatin and fluorouracil in taxane-and anthracycline-pretreated breast cancer patients. J Clin Oncol 20:2551-2558
18. Twelves C, Glynne-Jones R, Cassidy J, Schuller J, Goggin T, Roos B, Banken L, Utoh M, Weidekamm E, Reigner B (1999) Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 5:1696-1702